Effect of Fibrosis on Adverse Events in Patients With Hepatitis C Treated With Telaprevir

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.12560
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

CPC-107 Pharmacotherapy Follow-Up in Chronic Hepatitis C Patients Treated With Boceprevir or Telaprevir

European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
2013English

Evaluation of Persistence of Resistant Variants With Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated With Telaprevir

PLoS ONE
Multidisciplinary
2012English

The Effect on Gastric Emptying of Telaprevir-Based Triple Therapy for Chronic Hepatitis C Patients

2015English

Resistance Patterns and Genetic Variations in Patients With Hepatitis C Virus: Emerging Role of Telaprevir

Virus Adaptation and Treatment
VirologyInfectious DiseasesImmunology
2010English

Telaprevir in a Patient With Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis

Antiviral Therapy
Infectious DiseasesPharmacology
2013English

Association of Serum Autotaxin Levels With Liver Fibrosis in Patients With Chronic Hepatitis C

Scientific Reports
Multidisciplinary
2017English

Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2016English

Hepatitis C Virus Markers in Patients With Acute Post-Transfusion Hepatitis Treated With Interferon Alfa-2b.

Gut
Gastroenterology
1993English

Non-Invasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir With Pegylated Interferon and Ribavirin for Chronic Hepatitis C

Antiviral Therapy
Infectious DiseasesPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy